A Study to Evaluate the Endocrine Immune Related Adverse Events in Patients With Metastatic Melanoma Treated With Ipilimumab and Nivolumab Combination Therapy
Latest Information Update: 20 Jun 2016
Price :
$35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 20 Jun 2016 New trial record